Company news

Turn Therapeutics Inc. news in 2026

Turn Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 16, 2026

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

November 9, 2026

Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program

November 5, 2026

U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat

October 21, 2026

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

September 10, 2026

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

September 9, 2026

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

August 20, 2026

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12, 2026

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 7, 2026

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 6, 2026

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 1, 2026

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 11, 2026

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 30, 2026

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

March 23, 2026

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs

February 17, 2026

Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

February 9, 2026

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

January 7, 2026

Decks in 2026